Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Jun 5 2023

Full Issue

Cancer Researchers Report Promising Results In Various Drug Studies

3 drug study results presented over the weekend at the American Society for Clinical Oncology annual meeting show potential for treating certain forms of brain, lung and ovarian cancer.

Stat: Targeted Drug Greatly Slows Growth Of A Brain Cancer

An experimental drug dramatically slowed the growth of glioma, a type of brain cancer, if the tumor carried a specific type of genetic alteration, researchers said Sunday, potentially sparing patients exposure to radiation and chemotherapy. (Herper, 6/4)

Stat: ‘Extraordinary’ Data Reported For AstraZeneca Lung Cancer Drug

Giving the AstraZeneca drug Tagrisso to patients with non-small cell lung cancer who have had their tumors removed reduced the risk of death by 51%, researchers said Sunday. Put another way, that would mean that about one in 10 patients who received the drug would live another five years. (Chen and Herper, 6/4)

Stat: ImmunoGen Drug Prolongs Survival In Advanced Ovarian Cancer

An antibody that delivers chemotherapy directly to tumor cells extended the lives of women with a form of advanced ovarian cancer in a large study, researchers reported Sunday. The drug, called Elahere, is made by the biotech company ImmunoGen. It was granted conditional approval in the U.S. last November based on preliminary evidence showing it shrank tumors. (Feuerstein, 6/4)

In other news about cancer drugs and vaccines —

Axios: Post-Public Health Emergency Fallout Hits Patients

Cancer doctors and dozens of lawmakers in Congress are questioning whether the federal health department overreached when it blocked medical practices from mailing specialty drugs like oral cancer and blood clotting treatments directly to patients at the end of the COVID public health emergency. (Reed, 6/5)

Politico: How Covid Made It Nearly Impossible To Pass New Vaccine Rules 

The HPV vaccine has been around for almost two decades and could spare thousands of people from developing cervical and oral cancer — so mandating it for schoolchildren once seemed an easy call for Democrats in deep-blue California. But a bill to do just that has been watered down beyond recognition in one of the most liberal states in the U.S., a victim of a homegrown anti-vaccine movement that has become more organized and more successful since the pandemic. (Bluth, 6/4)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF